Another Vaccine: Study Finds Novavax Shot Is 90 Percent Effective
2021-06-15
LRC
TXT
大字
小字
滚动
全页
1American vaccine maker Novavax says a large study found its COVID-19 shot is 90 percent effective against the coronavirus and several virus variants.
2The results, announced Monday, were based on late-stage trials involving nearly 30,000 volunteers in the United States and Mexico.
3Novavax said the two-shot vaccine was about 90 percent effective and data showed it was safe.
4The company says it plans to seek emergency approval for the vaccine in the U.S., Europe and elsewhere by the end of September.
5It estimates it would then be able to start producing up to 100 million injections a month.
6The company says it aims to supply 110 million doses to the U.S. over the next year and a total of 1.1 billion doses to developing countries.
7The vaccine -- which is easy to store and transport -- is expected to play an important part in increasing the availability of shots in the developing world.
8"Many of our first doses will go to ... low- and middle-income countries, and that was the goal to begin with," Novavax Chief Executive Stanley Erck told The Associated Press.
9While more than half of the U.S. population has had at least one vaccine injection, less than 1 percent of people in the developing world have had one shot, researcher Our World In Data reports.
10The Pfizer, Moderna and Johnson & Johnson vaccines have already been approved for emergency use in the U.S. and Europe.
11Europe also uses a vaccine developed by AstraZeneca.
12Novavax's study involved nearly 30,000 people ages 18 and up.
13Two-thirds of subjects received two injections of the vaccine, three weeks apart, with the rest receiving an inactive substance or placebo.
14There were 77 cases of COVID-19 -- 14 in the group that got the vaccine and the rest in volunteers who received the placebo.
15None of the people in the vaccine group experienced moderate or severe disease.
16The vaccine was similarly effective against several variants.
17One of the variants first appeared in Britain and is also found in the U.S. It has especially been affecting high-risk populations, including older people and those with other health problems.
18Only minor side effects were reported in people taking part in the study, such as head and muscle aches, tiredness and pain at the injection site.
19The company said there were no reports of unusual blood clots or heart problems.
20Novavax reported its results in a news release.
21It said it plans to publish the findings in a medical publication to be examined by independent experts.
22I'm Bryan Lynn.
1American vaccine maker Novavax says a large study found its COVID-19 shot is 90 percent effective against the coronavirus and several virus variants. 2The results, announced Monday, were based on late-stage trials involving nearly 30,000 volunteers in the United States and Mexico. 3Novavax said the two-shot vaccine was about 90 percent effective and data showed it was safe. The company says it plans to seek emergency approval for the vaccine in the U.S., Europe and elsewhere by the end of September. 4It estimates it would then be able to start producing up to 100 million injections a month. The company says it aims to supply 110 million doses to the U.S. over the next year and a total of 1.1 billion doses to developing countries. 5The vaccine -- which is easy to store and transport -- is expected to play an important part in increasing the availability of shots in the developing world. 6"Many of our first doses will go to ... low- and middle-income countries, and that was the goal to begin with," Novavax Chief Executive Stanley Erck told The Associated Press. 7While more than half of the U.S. population has had at least one vaccine injection, less than 1 percent of people in the developing world have had one shot, researcher Our World In Data reports. 8The Pfizer, Moderna and Johnson & Johnson vaccines have already been approved for emergency use in the U.S. and Europe. Europe also uses a vaccine developed by AstraZeneca. 9Novavax's study involved nearly 30,000 people ages 18 and up. Two-thirds of subjects received two injections of the vaccine, three weeks apart, with the rest receiving an inactive substance or placebo. 10There were 77 cases of COVID-19 -- 14 in the group that got the vaccine and the rest in volunteers who received the placebo. None of the people in the vaccine group experienced moderate or severe disease. 11The vaccine was similarly effective against several variants. One of the variants first appeared in Britain and is also found in the U.S. It has especially been affecting high-risk populations, including older people and those with other health problems. 12Only minor side effects were reported in people taking part in the study, such as head and muscle aches, tiredness and pain at the injection site. The company said there were no reports of unusual blood clots or heart problems. 13Novavax reported its results in a news release. It said it plans to publish the findings in a medical publication to be examined by independent experts. 14I'm Bryan Lynn. 15The Associated Press and Reuters reported on this story. Bryan Lynn adapted the reports for VOA Learning English. Hai Do was the editor. 16___________________________________________________________ 17Words in This Story 18variant - n. different in some way from others of the same kind 19dose - n. the amount of a medicine, drug or vitamin this is taken at one time 20placebo - n. a substance that is given to a patient in a medical study that has no physical effect 21ache - n. a feeling or pain over an area of the body that continues for a long time 22clot - n. (medical) a mass of dried blood that stops blood from flowing through blood vessels 23We want to hear from you. Write to us in the Comments section, and visit our Facebook page.